These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15627669)

  • 21. Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin.
    Barreiros AP; Schlaak JF; Gerken G; Galle PR; Löhr HF
    Eur J Clin Invest; 2003 Jul; 33(7):628-9. PubMed ID: 12814401
    [No Abstract]   [Full Text] [Related]  

  • 22. Peginterferon plus ribavirin over two years may be successful in patients with chronic hepatitis C and a very slow virologic response.
    Ordubadi P; Gschwantler M
    Scand J Gastroenterol; 2009; 44(9):1150-1. PubMed ID: 19593689
    [No Abstract]   [Full Text] [Related]  

  • 23. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ribavirin: a new drug in the treatment of chronic hepatitis C].
    Salmerón J
    Gastroenterol Hepatol; 1997; 20(7):363-5. PubMed ID: 9377236
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
    Zhu F; Zhang QY; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):173-174. PubMed ID: 29807402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality rate during interferon alfa-ribavirin combination therapy of chronic hepatitis C.
    Soza A; Hoofnagle JH
    Hepatology; 2003 Jul; 38(1):267. PubMed ID: 12830010
    [No Abstract]   [Full Text] [Related]  

  • 27. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
    Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
    Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial.
    Enomoto M; Tamori A; Kawada N; Jomura H; Nishiguchi S; Saibara T; Onishi S; Mochida S; Fujiwara K
    Gut; 2006 Jan; 55(1):139-40. PubMed ID: 16344588
    [No Abstract]   [Full Text] [Related]  

  • 31. Viral hepatitis C.
    Mascitelli L; Pezzetta F
    Lancet; 2004 Feb; 363(9409):661. PubMed ID: 14987902
    [No Abstract]   [Full Text] [Related]  

  • 32. [Glycyrrhizic acid].
    Tolstikov GA; Baltina LA; Shul'ts EE; Pokrovskił AG
    Bioorg Khim; 1997 Sep; 23(9):691-709. PubMed ID: 9441592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with interferon-alpha and ribavirin as immunomodulators in patients with chronic hepatitis C.
    Horiike N; Onji M
    J Gastroenterol; 2003; 38(3):302-4. PubMed ID: 12693384
    [No Abstract]   [Full Text] [Related]  

  • 35. Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Wahid B; Saleem K; Ali A; Rafique S; Idrees M
    Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):979-980. PubMed ID: 28471832
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
    Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW
    Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ribavirin in combination with interferon alpha-2b in the treatment of chronic hepatitis C].
    Hillon P
    Presse Med; 2001 Feb; 30(7):335-6. PubMed ID: 11262810
    [No Abstract]   [Full Text] [Related]  

  • 38. [Peginterferon alpha combined with ribavirin for the treatment of chronic hepatitis C].
    Xu Y; Wang JB
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jun; 19(6):415-6. PubMed ID: 22053369
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.
    Friebus-Kardash J; Eisenberger U; Ackermann J; Kribben A; Witzke O; Wenzel J; Rohn H; Fiedler M
    Transpl Infect Dis; 2019 Jun; 21(3):e13088. PubMed ID: 30929308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.